Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (1223)	10/17/2003 1:04:45 AM
From: rjk01	of 1386

16 Oct 03 15:54 Pharmos (Nasdaq: PARS) rose to $3.47 on a heavy turnover, to complete a 14% rise. Next Tuesday, Pharmos chairman and CEO Dr. Haim Aviv will appear before institutional investors at the Rodman & Renshaw Techvest Healthcare Conference in Boston. For the first time, Aviv will talk about Pharmos's discoveries in neurology acquired during its research on Dexanabinol. Some of the conference's attendees might include institutional investors who've invested in ImClone (Nasdaq:IMCL). They will discover that Pharmos's drug is no less impressive, and farther along the FDA approval process, and may decide to switch to Pharmos

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next